Table 1 Summary of references analyzing mitotic rate as a prognostic marker

Malmström 1994 [14]

Not specified

n = 54; assessment of MI in n = 42

I (83%);

II (11%);

III (2%)

≤4 HPF;

5–9 HPF;

≥10 HPF

Survival reduced in subgroup, no p-value given

King 1996 [15]

n = 38 AGCT;

n = 2 JGCT

n = 40

I (77.5%);

II (7.5%);

III (15%)

Not specified

Stage

(p = 0.005)

Survival

(p = 0.006)

Fujimoto 2001 [16]

AGCT

n = 27

I (63%);

II (15%);

III (19%);

IV (3%)

4/10 HPF

Survival

(p < 0.005)

Recurrence

(p < 0.001)

Sehouli 2004 [9]

Not specified

n = 65

I (80%);

II (7.7%); III (9.2%); IV (3.1%)

5/10 HPF

Survival (p < 0.001)

Van Meurs 2014 [17]

AGCT

n = 127

I (76%);

II-IV (24%)

5/10 HPF

Recurrence (p < 0.001)

Thomakos 2016 [18]

AGCT

n = 43

I (95%);

II (5%)

4/10 HPF

Recurrence (p = 0.027)

Sakr 2017 [19]

n = 113 AGCT

n = 12 JGCT

n = 125

I-II (95%);

III-IV (5%)

4/10 HPF

Recurrence

(p = 0.021)

DFI

(p = 0.005)

Dridi 2018 [20]

AGCT

n = 31; assessment of MI in n = 22

I (61%);

II (10%);

III (19%);

IV (10%)

Not specified

Survival (p = 0.01)

Costa 1995 [21]

n = 49 AGCT

n = 7 JGCT

n = 56

I (84%);

II (3%):

III (13%)

5/10 HPF

No significance

Lauszus 2001 [22]

Not specified

n = 37

I (100%)

Not specified

No significance

Lin 2005 [23]

AGCT

n = 36

I (97%);

II (3%)

< 1 HPF;

2–3 HPF

≥4 HPF

No significance

Kim 2006 [24]

AGCT

n = 35

I (86%);

II (3%);

III (11%)

Not specified

No significance

Pectasides 2008 [25]

AGCT

n = 34

I (59%);

II (8%);

III (22%);

IV (11%)

1–3 HPF;

4–10 HPF;

> 10 HPF

No significance

Leuverink 2008 [27]

AGCT

n = 38

I (76%);

II (11%);

III (11%);

IV (2%)

Not specified

No significance

Suri 2013 [26]

AGCT

n = 104; assessment of MI in n = 50

I (95%);

II (1%);

III (4%)

4/10 HPF

No significance